Redeye Feed

2025-10-19 16:44:00 Vitec (Q3 review) - Starting to look at 2026e

2025-10-19 16:43:00 Xspray Pharma - Update after Dasynoc CRL

2025-10-16 20:24:00 Carasent (Q3 Review) - In good shape for exciting 2026

2025-10-07 21:14:00 Starbreeze - Updated valuation

2025-10-06 10:56:00 Transtema Q3 2025 Preview - Tough market conditions in Norway persist

2025-10-06 10:54:00 Mendus - Expanding vididencel’s market potential

2025-10-02 19:34:00 Lime Q3 2025 Preview - Small revisions, notable upside potential to Base Case

2025-09-25 09:59:00 Saniona - Optionality unlocked

2025-09-24 10:46:00 Addnode CMD - Growth ambitions unchanged despite the bigger size

2025-09-22 11:34:00 Verve Group - Two acquisitions in two days

2025-09-15 10:22:00 Binero Group H1’25 Review - Solid Progress

2025-09-15 10:21:00 Redeye Initiates Coverage of Fractal Gaming Group

2025-09-12 16:21:00 Biovica Q1 Update - Capitalised but the launch is still not in full swing

2025-09-11 10:46:00 Redeye Initiates Coverage of Guard Therapeutics

2025-09-09 13:13:00 BioArctic - Strong momentum, fair price

2025-09-09 13:10:00 Litium - More Brains, More Geins

2025-09-04 11:06:00 Redeye Initiates Coverage of Senzime

2025-09-04 11:05:00 Sprint Bioscience - A clear objective to secure a new partner

2025-09-03 16:11:00 Flexion Mobile - Building growth momentum

2025-09-02 10:35:00 Dala Energi - All eyes on the NAV

2025-09-02 10:34:00 Mindark - Sequential sales rebound

2025-09-02 10:33:00 Integrum Q1 - Miss on sales

2025-09-02 10:31:00 Heliospectra - Momentum building, but larger greenhouse projects still ahead

2025-09-02 10:29:00 Corline Biomedical - Kardium receives FDA approval

2025-09-01 11:16:00 Elicera Q2 - Developing CARMA – Data strengthens ELC-301 outlook

2025-09-01 11:15:00 Insplorion - Large follow-up order in the pipeline

2025-09-01 11:14:00 Nekkar - Q2 Review – Postponed Recovery

2025-09-01 11:13:00 IRLAB Therapeutics Q2 - Focus on value creation following strengthened financials

2025-09-01 11:12:00 Systemair - Ready for more M&A

2025-08-29 12:54:00 Jumpgate Q2 2025 - Additions to the project pipeline

2025-08-29 12:52:00 GiG Software - Strengthened balance sheet and focus on larger clients

2025-08-29 12:51:00 Lytix Biopharma Q2 2025 - Extended Update

2025-08-29 12:51:00 Fable Media Group - Dividend Season, Four Times a Year

2025-08-28 17:09:00 FluoGuide Q2 2025 - Gearing up for the next phase

2025-08-28 17:08:00 Lipum Q2 - Focus on securing funding

2025-08-28 10:34:00 Redeye Initiates Coverage of BICO Group

2025-08-28 10:32:00 GomSpace Q2 Review - Orbiting Higher

2025-08-28 10:31:00 Smart Eye - On the Autobahn to 2026

2025-08-28 10:30:00 AcouSort Q2 - Robust cost control

2025-08-27 17:07:00 Faron Pharmaceuticals H1 - Advancing to registrational trials

2025-08-27 12:35:00 BioInvent Q2 2025 - Narrowed Focus on BI-1206 and BI-1808

2025-08-27 11:58:00 AlzeCure Q2 - Prepares for clinical studies

2025-08-27 11:56:00 Xbrane Biopharma Q2 2025 - Important months ahead

2025-08-27 11:55:00 Gentoo Media - Another weak quarter, but potential for recovery in H2

2025-08-27 11:54:00 Corline Biomedical Q2 - Kardium’s Globe system nearing launch

2025-08-26 14:28:00 Lipigon Q2 2025 - Last Patient In

2025-08-26 14:27:00 Isofol Medical Q2 - Refueled by a strengthened cash position

2025-08-26 14:26:00 Neola Medical Q2 - Potential share price trigger incoming

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Redeye

Prenumeration

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden